Raj Mehta
Co-Founder and CEO
Raj Mehta, an entrepreneur in residence at ATP, has identified, nurtured, raised funds for, and launched multiple immunology- and oncology-focused spinoffs and built many lasting partnerships.
At GammaDelta Therapeutics, as co-founder, interim CEO, board member and director of business development, he led a $100-million fundraising effort, established a partnership with Takeda Pharmaceuticals, managed the acquisition of Lymphact, and spearheaded the spinoff of Adaptate Biotherapeutics. Prior to GammaDelta, Raj spent nearly 18 years at Cancer Research Technology (CRT), where he served as co-founder, interim CEO, and board member of BliNK Therapeutics and Revitope Oncology; established Fastbase Solutions; and led on forming more than 25 licensing and collaborative partnerships. Raj joined CRT from MRC Collaborative Centre, where he led the Merck KGaA Group.
Raj earned a natural sciences degree from University of Cambridge and completed his doctoral research at the National Institute for Medical Research, now part of Francis Crick Institute, in London.
